| 4.81 -0.17 (-3.41%) | 11-29 10:10 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 6.7 |
1-year : | 7.55 |
| Resists | First : | 5.74 |
Second : | 6.46 |
| Pivot price | 5.15 |
|||
| Supports | First : | 4.55 | Second : | 3.79 |
| MAs | MA(5) : | 4.98 |
MA(20) : | 5.13 |
| MA(100) : | 7.06 |
MA(250) : | 6.86 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.4  |
| %K %D | K(14,3) : | 12.8 |
D(3) : | 18.3 |
| RSI | RSI(14): 37.9 |
|||
| 52-week | High : | 9.6 | Low : | 4.55 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ MTEM ] has closed above bottom band by 20.1%. Bollinger Bands are 29% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.37 - 5.4 | 5.4 - 5.42 |
| Low: | 4.85 - 4.88 | 4.88 - 4.9 |
| Close: | 4.91 - 4.95 | 4.95 - 4.99 |
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and MT-6402 in that is in Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients. Its pipeline of ETBs in development for other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.
Mon, 13 Nov 2023
Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business Update - Yahoo Finance
Thu, 02 Nov 2023
Molecular Templates Announces First Patient Dosed in Phase 1 ... - BioSpace
Fri, 11 Aug 2023
Molecular Templates Announces 1-for-15 Reverse Stock Split - Yahoo Finance
Tue, 01 Aug 2023
Solu Therapeutics Debuts with $31 Million in Seed Funding to ... - Business Wire
Thu, 13 Jul 2023
Molecular Templates Announces Up to $40 Million Private ... - GlobeNewswire
Tue, 11 Apr 2023
Molecular Templates to cut 50% of staff; Austin co. pursues 'strategic ... - The Business Journals
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 5 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 66 (K) |
| Shares Short P.Month | 58 (K) |
| EPS | -6.93 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.25 |
| Profit Margin | -49.6 % |
| Operating Margin | -75.6 % |
| Return on Assets (ttm) | -20.1 % |
| Return on Equity (ttm) | -478.9 % |
| Qtrly Rev. Growth | 60.2 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 9.85 |
| EBITDA (p.s.) | -3.5 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -55 (M) |
| Levered Free Cash Flow | -32 (M) |
| PE Ratio | -0.7 |
| PEG Ratio | -0.4 |
| Price to Book value | 3.81 |
| Price to Sales | 0.48 |
| Price to Cash Flow | -0.47 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|